BPC January 06 update

Freeline FRLN IND cleared; Alterity ATHE Patent

Pre-Market Updates

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced that the FDA cleared its Investigational New Drug (IND) application for FLT201 to treat Gaucher disease Type 1.

Alterity Therapeutics (NASDAQ: ATHE) announced that the United States Patent and Trademark Office (USPTO) granted it a new patent covering more than 80 novel compounds designed to redistribute excess iron implicated in many neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that it entered into a private placement for 12,105,264 shares of stock and warrants at $0.95 per share of common stock and associated warrants. The gross proceeds are approximately $11.5 million.

First Wave BioPharma, Inc. (NASDAQ: FWBI) completed enrollment for Part 2 of its RESERVOIR Phase 2 trial of FW-COV to treat COVID-19-related gastrointestinal (GI) infections. There were no drug-related SAEs reported to date with top-line data due in the first half of 2022.

Aligos Therapeutics, Inc. (NASDAQ: ALGS) announced that development has been halted for ALG-010133 due to no meaningful HBsAg reduction and higher doses levels are very unlikely to reach the 1 log10 IU/mL HBsAg reduction level that had been previously defined as necessary to advance the program.

Plus Therapeutics, Inc. (NASDAQ: PSTV) entered into an agreement with The University of Texas Health Science Center at San Antonio for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer.

Sutro Biopharma, Inc. (NASDAQ: STRO) shares are trading down after Wedbush lowered its price target from $38 to $30 but kept an Outperform rating.

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced that Sanofi (NASDAQ: SNY) will transition its rights and obligations related to SAR445136 back to Sangamo during the first half of 2022.

Pre-Market Advancers

CompanyPriceChange
ARKG
ARK Genomic Revolution ETF
$47.57+0.965  +2.07%

Pre-Market Decliners

CompanyPriceChange
ARKG
ARK Genomic Revolution ETF
$47.57+0.965  +2.07%